Development & Future

Pipeline & Vision

From research to application. Explore our current product pipeline, ongoing development projects and the strategic vision for the future of Bacillus subtilis MM40® (DSM 21097; Budapest Treaty DSM 33619; EU Trademark No. 018279328).

Available Products & Raw Materials

These products and raw materials based on MM40® are already available to B2B partners today.

💊

Dietary Supplements

Formulations with B. subtilis MM40® as dietary supplements. Based on the clinically investigated strain with documented results from a randomized clinical study.

Cosmetic Raw Materials

Surfactin as a cosmetic raw material with surface-active and antimicrobial properties. Suitable for formulations in skincare and dermatological products.

🔬

MCT-Encapsulated Formulations

Patented MCT oil-silicon encapsulation technology (EU Patent EP3964195) for maximum stability. Ideal for climatically demanding markets and shelf-stable applications.

Future Application Fields

Beyond the current portfolio, additional application fields are being explored and developed. The following programs are in various stages of development.

🩹

Woundcare / Medical Devices

Concept for a Class IIa medical device for wound care, based on the antimicrobial properties of MM40® observed in vitro.

  • Joint Venture concept being developed
  • Regulatory pathway: MDR (EU Medical Device Regulation)
  • Based on in vitro data from UKSH Lübeck
  • Seeking partners for joint development
📊

Extended Clinical Program

Building on the results of the completed pilot study, larger confirmatory studies are intended to investigate the observed effects in broader populations.

  • Larger confirmatory studies planned
  • Additional endpoints and populations
  • Building on existing RCT data
🌱

Agricultural & Veterinary Applications

Exploring the potential in soil health and aquaculture. B. subtilis is already widely used in agriculture - the specific potential of MM40® is being investigated.

  • Soil health and plant vitality
  • Aquaculture potential
  • Building on known B. subtilis applications
Regulatory Disclaimer: These are development concepts in various stages of progress. No medical device has been approved. Regulatory clearance is subject to completion of required conformity assessment procedures. All statements regarding future developments represent planning intentions and are subject to regulatory approval.

Our Strategic Vision

From early research to global scaling - a look at key milestones and planned next steps.

2024 - 2025
  • Clinical study completed (RCT, 70 participants)
  • EU Patent EP3964195 granted
  • First B2B partnerships established
  • Industrial production capacities built
2026
  • Website launch and digital presence
  • International expansion (Dubai / GCC region)
  • Woundcare Joint Venture concept in development
  • Expansion of partnership network
2027+
  • Confirmatory clinical trials intended
  • MDR pathway for medical device (subject to regulatory approval)
  • Global scaling and new markets
  • Extension of platform applications

Partnership Opportunities

We are open to diverse cooperation models and are actively seeking partners for further development and commercialization.

📄

Licensing

Licensing of the patented strain MM40® and/or the MCT encapsulation technology for defined application fields and markets.

🤝

Joint Ventures

Joint development and commercialization of new applications - particularly in the area of wound care and medical devices.

🏭

White-Label / Private-Label

Manufacturing under your brand. We supply the raw material and formulation expertise - you bring your brand and distribution.

🔬

Research Collaborations

Joint research projects for further characterization of the strain and exploration of new application fields.

🌍

Distribution Partnerships

Regional or international distribution partners for access to new markets and customer segments.

Shape the Future Together

Want to be part of our development journey? Contact us for a non-binding partnership inquiry.